BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Jun 16 2015

BiondVax Pharmaceuticals Ltd. (TASE: BNDX, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

Dr. Ron Babecoff, CEO of Biondvax (Photo credit: PR)

The workshop will bring together experts from research institutions, industry, public health and regulatory agencies with the aim of evaluating immunoassays that can be used to assess broadly reactive or universal influenza vaccines and their standardization. The workshop focuses on assays for cell mediated immune responses that are specific to multiple influenza strains.. Dr. Tamar Ben-Yedidia, the Chief Scientist of BiondVax, will present data and discuss the Company’s own experience and views on assays for the assessment of future vaccines.

Ron Babecoff, BiondVax's CEO commented:

This invitation is further recognition by the European Commission and the NIH of BiondVax's central position and contribution to this important field of new influenza vaccine development. Our scientific and clinical experience is well recognized both in Europe and in the US. We hope that together with the other participants, we can facilitate the acceptance of new standard assays that will promote regulatory approval for universal flu vaccines.